ImmunoPrecise Antibodies Balance Sheet Health
Financial Health criteria checks 5/6
ImmunoPrecise Antibodies has a total shareholder equity of CA$49.8M and total debt of CA$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CA$78.7M and CA$28.9M respectively.
Key information
0%
Debt to equity ratio
CA$0
Debt
Interest coverage ratio | n/a |
Cash | CA$6.20m |
Equity | CA$49.82m |
Total liabilities | CA$28.87m |
Total assets | CA$78.69m |
Financial Position Analysis
Short Term Liabilities: IPA's short term assets (CA$15.1M) exceed its short term liabilities (CA$9.1M).
Long Term Liabilities: IPA's short term assets (CA$15.1M) do not cover its long term liabilities (CA$19.8M).
Debt to Equity History and Analysis
Debt Level: IPA is debt free.
Reducing Debt: IPA has no debt compared to 5 years ago when its debt to equity ratio was 13.8%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IPA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IPA has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 32.5% each year.